Valion Bio (TIVC) Liabilities and Shareholders Equity (2021 - 2025)
Valion Bio has reported Liabilities and Shareholders Equity over the past 5 years, most recently at $31.6 million for Q4 2025.
- For Q4 2025, Liabilities and Shareholders Equity rose 1026.01% year-over-year to $31.6 million; the TTM value through Dec 2025 reached $46.1 million, up 223.2%, while the annual FY2025 figure was $31.6 million, 1026.01% up from the prior year.
- Liabilities and Shareholders Equity for Q4 2025 was $31.6 million at Valion Bio, up from $6.2 million in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $31.6 million in Q4 2025 and troughed at $2.8 million in Q4 2024.
- A 5-year average of $8.1 million and a median of $5.9 million in 2022 define the central range for Liabilities and Shareholders Equity.
- Biggest five-year swings in Liabilities and Shareholders Equity: plummeted 60.93% in 2022 and later surged 1026.01% in 2025.
- Year by year, Liabilities and Shareholders Equity stood at $15.0 million in 2021, then plummeted by 60.93% to $5.9 million in 2022, then dropped by 12.22% to $5.2 million in 2023, then plummeted by 45.57% to $2.8 million in 2024, then surged by 1026.01% to $31.6 million in 2025.
- Business Quant data shows Liabilities and Shareholders Equity for TIVC at $31.6 million in Q4 2025, $6.2 million in Q3 2025, and $4.5 million in Q2 2025.